Doxorubicin-Induced CardiomyopathySymptoms, Doctors, Treatments, Advances & More
Learn About Doxorubicin-Induced Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
CVI - Cardiovascular Clinic
Aarti Asnani is an Internal Medicine provider practicing medicine in Boston, Massachusetts. She has been practicing medicine for over 18 years. Dr. Asnani is rated as an Elite provider by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Myocarditis, Cardiomyopathy, and Pacemaker Implantation. Dr. Asnani is board certified in American Board Of Internal Medicine.
Pediatric Audiology-Oishei Childrens Outpatient Center (Conventus)
Steven Lipshultz is a Pediatrics provider practicing medicine in Buffalo, New York. Dr. Lipshultz is rated as an Elite provider by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Dilated Cardiomyopathy (DCM), Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Heart Transplant, and Gastric Bypass.
Ballad Health CVA Heart Institute
Eduardo Fernandez is a Cardiologist practicing medicine in Bristol, Tennessee. Dr. Fernandez is rated as an Advanced provider by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Familial Neurocardiogenic Syncope, Apoplexy, Aortic Regurgitation, and Cardiomyopathy. Dr. Fernandez is board certified in American Board Of Internal Medicine.
Summary: Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corr...